NGHIÊN CỨU GỐC (ORIGINAL PAPERS)

The Efficacy, Effectiveness, and Safety of Human Papillomavirus (HPV) Vaccines

DOI: https://doi.org/10.38148/JHDS.0901SKPT25-127 ↗
Anh Le Tu1, Ngoc Nguyen Bao2, Van Nguyen Thi3
1 Trường Đại học Y tế công cộng
2 Trường Đại học Y tế công cộng
3 Trường Đại học Y tế công cộng

Tóm tắt

Objective: This review aims to (1) synthesize and evaluate the available scientific evidence on the efficacy, effectiveness, and safety of HPV vaccines in both clinical trials and real-world settings; (2) compare the differences in outcomes between vaccines, age groups, and deployment contexts; and (3) discuss public health implications and applicability in the Vietnamese context.

Methods: This narrative review was conducted through a comprehensive search and analysis of published literature in major medical databases, including PubMed, Scopus, Google Scholar, and official reports from the WHO and CDC. Evidence from clinical trials, long-term follow-up studies, and real-world data was compiled thematically using the SANRA scale.

Results: HPV vaccines have shown high efficacy and effectiveness in preventing HPV infection and precancerous cervical lesions. Bivalent HPV vaccines are 93–98% effective against moderate to severe cervical lesions caused by HPV-16/18. The quadrivalent HPV vaccine showed 100% protection against grade 2 or higher cervical lesions during 24,099 person-years of follow-up, reducing HPV-6, 11, 16, and 18 infections by approximately 90% and maintaining a sustained immune response for at least 12 years. The nine-valent HPV vaccine offered protection against five additional high-risk HPV types, achieving ≥90% efficacy for 10–12 years with seropositivity rates of ≥81–90% for the covered types. Real-world data also confirms high preventive effectiveness among children and adolescents. The safety profile of HPV vaccines has been well established in both clinical trials and post-licensure surveillance, with most post-vaccination reactions being mild and transient (pain, swelling, fatigue, headache), while serious adverse events were rare and comparable to placebo.

 

Conclusion: HPV vaccines are safe and highly effective in preventing HPV infection and precancerous cervical lesions, offering superior preventative benefits compared to minimal risks. Early vaccination, a single-dose regimen, expanded coverage, and increased public awareness are key strategies to optimize the effectiveness and coverage of HPV vaccination programs

Đã Xuất bản 2026-02-28
Toàn văn
PDF
Ngôn ngữ Tiếng Việt
Số Tập 10 Số 01 (2026): Tập 10, Số 01-2026
Chuyên mục Nghiên cứu gốc (Original papers)
DOI https://doi.org/10.38148/JHDS.0901SKPT25-127 ↗
Trang số 51-60
Từ khóa
cervical cancer HPV vaccine Efficacy Effectiveness Safety

Cách trích dẫn

Le Tu, A., Nguyen Bao, N., & Nguyen Thi, V. (2026). The Efficacy, Effectiveness, and Safety of Human Papillomavirus (HPV) Vaccines. Tạp Chí Khoa học Nghiên cứu Sức khỏe Và Phát triển, 10(01), 51-60. https://doi.org/10.38148/JHDS.0901SKPT25-127
  1. 1. Chesson HW, Dunne EF, Hariri S, Markowitz LE. The estimated lifetime probability of acquiring human papillomavirus in the United States. Sex Transm Dis. 2014 Nov;41(11):660–4.
  2. 2. Cervical cancer [Internet]. [cited 2025 Sept 19]. Available from: https://www.who.int/news-room/ fact-sheets/detail/cervical-cancer
  3. 3. Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229–63.
  4. 5. Patel H, Wagner M, Singhal P, Kothari S. Systematic review of the incidence and prevalence of genital warts. BMC Infect Dis. 2013 Jan 25;13(1):39.
  5. 6. Arbyn M, Weiderpass E, Bruni L, Sanjosé S de, Saraiya M, Ferlay J, et al. Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis. The Lancet Global Health. 2020 Feb 1;8(2):e191–203.
  6. 7. Schiller JT, Castellsagué X, Garland SM. A Review of Clinical Trials of Human Papillomavirus Prophylactic Vaccines. Vaccine. 2012 Nov 20;30:F123–38.
  7. 8. CDC. Vaccine Safety. 2025 [cited 2025 Sept 20]. Human Papillomavirus (HPV) Vaccine Safety. Available from: https://www.cdc.gov/vaccine- safety/vaccines/hpv.html
  8. 9. Drolet M, Bénard É, Pérez N, Brisson M, Ali H, Boily MC, et al. Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis. The Lancet. 2019 Aug 10;394(10197):497–509.
  9. 10. Falcaro M, Castañon A, Ndlela B, Checchi M, Soldan K, Lopez-Bernal J, et al. The effects of the national HPV vaccination programme in England, UK, on cervical cancer and grade 3 cervical intraepithelial neoplasia incidence: a register- based observational study. The Lancet. 2021 Dec 4;398(10316):2084–92.
  10. 11. Baethge C, Goldbeck-Wood S, Mertens S. SANRA-a scale for the quality assessment of narrative review articles. Res Integr Peer Rev. 2019;4:5.
  11. 12. Thomas J, Harden A. Methods for the thematic synthesis of qualitative research in systematic reviews. BMC Med Res Methodol. 2008 July 10;8:45.
  12. 13. Cheng L, Wang Y, Du J. Human Papillomavirus Vaccines: An Updated Review. Vaccines (Basel). 2020 July 16;8(3):391.
  13. 14. Kamolratanakul S, Pitisuttithum P. Human Papillomavirus Vaccine Efficacy and Effectiveness against Cancer. Vaccines (Basel). 2021 Nov 30;9(12):1413.
  14. 15. FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high- grade cervical lesions. N Engl J Med. 2007 May 10;356(19):1915–27.
  15. 16. Joura EA, Giuliano AR, Iversen OE, Bouchard C, Mao C, Mehlsen J, et al. A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med. 2015 Feb 19;372(8):711–
  16. 17. Giuliano AR, Palefsky JM, Goldstone S, Moreira ED, Penny ME, Aranda C, et al. Efficacy of Quadrivalent HPV Vaccine against HPV Infection and Disease in Males. N Engl J Med. 2011 Feb 3;364(5):401–11.
  17. 18. SIGNORELLI C, ODONE A, CIORBA V, CELLA P, AUDISIO RA, LOMBARDI A, et al. Human papillomavirus 9-valent vaccine for cancer prevention: a systematic review of the available evidence. Epidemiol Infect. 2017 July;145(10):1962–82.
  18. 19. Luxembourg A, Moeller E. 9-Valent human papillomavirus vaccine: a review of the clinical development program. Expert Review of Vaccines. 2017 Nov 2;16(11):1119–39.
  19. 20. Efficacy of GARDASIL®9 (Human Papillomavirus 9-valent Vaccine, Recombinant) [Internet]. Gardasil 9. [cited 2025 Sept 20]. Available from: https://www.merckvaccines.com/gardasil9/ efficacy/
  20. 21. Kavanagh K, Pollock KG, Cuschieri K, Palmer T, Cameron RL, Watt C, et al. Changes in the prevalence of human papillomavirus following a national bivalent human papillomavirus vaccination programme in Scotland: a 7-year cross-sectional study. The Lancet Infectious Diseases. 2017 Dec 1;17(12):1293–302.
  21. 22. Checchi M, Mesher D, Panwar K, Anderson A, Beddows S, Soldan K. The impact of over ten years of HPV vaccination in England: Surveillance of type-specific HPV in young sexually active females. Vaccine. 2023 Oct 26;41(45):6734–44.
  22. 23. Kudo R, Yamaguchi M, Sekine M, Adachi S, Ueda Y, Miyagi E, et al. Bivalent Human Papillomavirus Vaccine Effectiveness in a Japanese Population: High Vaccine-Type-Specific Effectiveness and Evidence of Cross-Protection. J Infect Dis. 2019 Jan 9;219(3):382–90.
  23. 24. Kjaer SK, Nygård M, Sundström K, Dillner J, Tryggvadottir L, Munk C, et al. Final analysis of a 14-year long-term follow-up study of the effectiveness and immunogenicity of the quadrivalent human papillomavirus
  24. 25. Garland SM, Kjaer SK, Muñoz N, Block SL, Brown DR, DiNubile MJ, et al. Impact and Effectiveness of the Quadrivalent Human Papillomavirus Vaccine: A Systematic Review of 10 Years of Real-world Experience. Clin Infect Dis. 2016 Aug 15;63(4):519–27.
  25. 26. Wen T, Xu X, Pan C, Hu S, Zhao H, Zhang X, et al. The 13-year long-term follow-up on the effectiveness and immunogenicity of the quadrivalent human papillomavirus vaccine in Chinese females vaccinated at 20-45 years of age. Hum Vaccin Immunother. 2024 Dec 31;20(1):2412391.
  26. 27. Kjaer SK, Falkenthal TEH, Sundström K, Munk C, Sture T, Bautista O, et al. Long-term effectiveness of the nine-valent human papillomavirus vaccine: Interim results after 12 years of follow-up in Scandinavian women. Human Vaccines & Immunotherapeutics. 2024 Dec 31;20(1):2377903.
  27. 28. Markowitz LE, Drolet M, Lewis R, Lemieux- Mellouki P, Perez N, Jit M, et al. Human Papillomavirus Vaccine Effectiveness by Number of Doses: Updated Systematic Review of Data from National Immunization Programs. Vaccine. 2022 Sept 2;40(37):5413–32.
  28. 29. Santos SA dos, Sato MY, Basilio PHG, Pereira ME, Julião RC, Arruda N da C, et al. Comparison between the safety of the HPV vaccine versus placebo: a systematic review and meta-analysis of randomized clinical trials. Jornal de Pediatria. 2025 Sept 1;101(5):101411.
  29. 30. Phillips A, Patel C, Pillsbury A, Brotherton J, Macartney K. Safety of Human Papillomavirus Vaccines: An Updated Review. Drug Saf. 2018 Apr;41(4):329–46.
  30. 31. Meng R, Ma R, Wang J, Liu P, Liu Z, He B, et al. Post-marketing surveillance for the safety of the quadrivalent human papillomavirus vaccine: a retrospective real-world study in China. Expert Rev Vaccines. 2025 Dec;24(1):849–56.
  31. 32. Arnheim-Dahlström L, Pasternak B, Svanström H, Sparén P, Hviid A. Autoimmune, neurological, and venous thromboembolic adverse events after immunisation of adolescent girls with quadrivalent human papillomavirus vaccine in Denmark and Sweden: cohort study. BMJ. 2013 Oct 9;347:f5906.
  32. 33. Shimabukuro TT, Su JR, Marquez PL, Mba-Jonas A, Arana JE, Cano MV. Safety of the 9-Valent Human Papillomavirus Vaccine. Pediatrics. 2019 Dec;144(6):e20191791.
  33. 34. Vichnin M, Bonanni P, Klein NP, Garland SM, Block SL, Kjaer SK, et al. An Overview of Quadrivalent Human Papillomavirus Vaccine Safety: 2006 to 2015. Pediatr Infect Dis J. 2015 Sept;34(9):983–91.
  34. 35. Su Y, Huang Y, Wei J, Wang X, Zhou Y, Wu X, et al. Real-world safety of HPV vaccines over 18 y: A comprehensive analysis of U.S. VAERS reports. Hum Vaccin Immunother. 21(1):2539590.
  35. 39. VNVC. Tác dụng phụ sau khi tiêm HPV bạn cần nắm để biết cách xử lý [Internet]. Vietnam Vaccine Joint Stock Company. 2024 [cited 2025 Sept 20]. Available from: https://vnvc.vn/tac-dung-phu- sau-khi-tiem-hpv/
  36. 40. Bệnh viện Đa khoa Tâm Anh [Internet]. 2025 [cited 2025 Sept 20]. Tác dụng phụ sau khi tiêm HPV và cách xử lý hiệu quả. Available from: https:// tamanhhospital.vn/tiem-chung/tac-dung-phu-sau- khi-tiem-hpv/
  37. 41. Thiem VD, Quang ND, Tuan NH, Cheon K, Gallagher N, Luxembourg A, et al. Immunogenicity and safety of a nine-valent human papillomavirus vaccine in Vietnamese males and females (9 to 26 years of age): an open-label, phase 3 trial. Hum Vaccin Immunother. 2021 July 3;17(7):1980–5.
  38. 42. Olsson SE, Restrepo JA, Reina JC, Pitisuttithum P, Ulied A, Varman M, et al. Long-term immunogenicity, effectiveness, and safety of nine- valent human papillomavirus vaccine in girls and boys 9 to 15 years of age: Interim analysis after 8 years of follow-up. Papillomavirus Res. 2020 July 11;10:100203.
  39. 43. Restrepo J, Herrera T, Samakoses R, Reina JC, Pitisuttithum P, Ulied A, et al. Ten-Year Follow- up of 9-Valent Human Papillomavirus Vaccine: Immunogenicity, Effectiveness, and Safety. Pediatrics. 2023 Oct 1;152(4):e2022060993.
  40. 44. Castle PE. Looking Back, Moving Forward: Challenges and Opportunities for Global Cervical Cancer Prevention and Control. Viruses. 2024 Sept;16(9):1357.
  41. 45. Bruni L, Saura-Lázaro A, Montoliu A, Brotons M, Alemany L, Diallo MS, et al. HPV vaccination introduction worldwide and WHO and UNICEF estimates of national HPV immunization coverage 2010–2019. Preventive Medicine. 2021 Mar 1;144:106399.
  42. 46. Nguyet Tu Tran NTT, Trung Ngoc Thi Phan TNTP, Tam Thi Pham TTP. Urban-rural disparities in acceptance of human papillomavirus vaccination among women in Can Tho, Vietnam. annali di igiene medicina preventiva e di comunità. 2023 Oct 30;(6):641–59.
  43. 47. Tình hình tiêm vắc xin phòng HPV ở trẻ nữ từ 9 – 17 tuổi và một số yếu tố liên quan tại thành phố Cần Thơ năm 2024 [Internet]. [cited 2025 Sept 20]. Available from: https://tapchiyhocvietnam. vn/index.php/vmj/article/view/14748/12652
  44. 48. Larson HJ, Jarrett C, Eckersberger E, Smith DMD, Paterson P. Understanding vaccine hesitancy around vaccines and vaccination from a global perspective: A systematic review of published literature, 2007–2012. Vaccine. 2014 Apr 17;32(19):2150–9.
  45. 49. Global strategy to accelerate the elimination of cervical cancer as a public health problem [Internet]. [cited 2025 Sept 20]. Available from: https://books.google.com/books/about/ Global_strategy_to_accelerate_the_elimin. html?id=hsNqEAAAQBAJ
  46. 50. Human papillomavirus vaccines: WHO position paper, December 2022 [Internet]. [cited 2025 Sept 20]. Available from: https://www.who.int/ publications/i/item/who-wer9750-645-672
  47. 51. Asres A, Jerene D, Deressa W. Tuberculosis treatment outcomes of six and eight-month treatment regimens in districts of Southwestern Ethiopia: a comparative cross-sectional study. BMC Infect Dis. 2016 Nov 8;16:653.
  48. 53. WHO khuyến cáo hiệu quả của tiêm vắc xin HPV đạt mức cao nhất khi tiêm cho trẻ từ 9-15 tuổi - Chương trình mục tiêu quốc gia [Internet]. [cited 2025 Sept 20]. Available from: https://moh. gov.vn/chuong-trinh-muc-tieu-quoc-gia/-/asset_ publisher/7ng11fEWgASC/content/who-khuyen- cao-hieu-qua-cua-tiem-vac-xin-hpv-at-muc-cao- nhat-khi-tiem-cho-tre-tu-9-15-tuoi
  49. 54. Bộ Y Tế & MSD Phát Động Chiến Dịch Vì Một Việt Nam Không HPV [Internet]. [cited 2026 Jan 5]. Available from: https://hpv.vn/bo-y-te-msd- phat-dong-chien-dich-vi-mot-viet-nam-khong- hpv-20250417175810125.html Le Tu Anh et al. DOI: https://doi.org/10.38148/JHDS.0901SKPT25-127